2021-09-28

Zydus Hospital, Ahmedabad, Gujarat, India.; Department of ENT, GCS Medical College, Ahmedabad, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Max Hospital, New Delhi, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Zydus Hospital, Ahmedabad, Gujarat, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; Department of Neurology, Ramkrishna Care Hospitals, Raipur, India.; BJ Medical College and Civil Hospital, Ahmedabad, India.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Zydus Hospital, Ahmedabad, Gujarat, India.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

IMPORTANCE: Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis and outcomes for mucormycosis among patients with COVID-19 infection. METHODS: This prospective, observational, multi-centre study included 47 consecutive patients with mucormycosis, diagnosed during their course of COVID-19 illness, between January 3 and March 27, 2021. Data regarding demography, underlying medical conditions, COVID-19 illness and treatment were collected. Clinical presentations of mucormycosis, imaging and biochemical characteristics and outcome were recorded. RESULTS: Of the 2567 COVID-19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycosis. Mean age was 55 ± 12.8years, and majority suffered from diabetes mellitus (n = 36, 76.6%). Most were not COVID-19 vaccinated (n = 31, 66.0%) and majority (n = 43, 91.5%) had developed